logo
Plus   Neg
Share
Email

Novartis: Aimovig Shows Long-term Efficacy In Treatment Of Episodic Migraine

Novartis (NVS) reported positive results from a 4.5-year, interim analysis of a 5-year, open-label treatment period to evaluate Aimovig in patients with episodic migraine. In the study, Aimovig reduced monthly migraine days, and also lowered the number of days requiring acute migraine-specific medication. The safety profile and tolerability were in line with previous clinical data for Aimovig.

Aimovig is a EMA and FDA-approved migraine prevention treatment. Novartis and Amgen are co-commercializing Aimovig in the US. Amgen has rights to Aimovig in Japan. Novartis has rights to commercialize in the rest of the world.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chinese electronics giant Huawei on Thursday launched its latest flagship smartphone range the Mate 30. Huawei unveiled the Huawei Mate 30 and Mate 30 Pro at an event in Munich. The new phones boasts of professional-grade cameras that competes directly with Apple's new iPhone 11 and iPhone 11 Pro... Schwartz Brothers Bakery of Seattle, Washington recalled 24 units of lemon dessert bars as it may contain undeclared egg. The products have a sell by date of September 21, 2019. The company issued the recall after it found that some of the Lemon Pound Cake was mislabeled as Lemon Dessert Bars. While the Lemon Pound Cake contains egg, the Lemon Dessert Bars label does not declare egg. Tesla has earned the highest safety award from the Insurance Institute for Highway Safety or IIHS for the first time. The luxury electric car maker's Model 3 midsize luxury sedan won the IIHS's Top Safety Pick+ award. The Model 3 is the second plug-in vehicle with no gas engine to earn the Top Safety Pick+ award after Audi's e-tron SUV.
Follow RTT